Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients

Farrokhlagha Ahmadi¹, Fatemeh Shamekhi², Mahbob Lessan-Pezeshki¹, Mohammad Reza Khatami^1
1 Department of Nephrology Research Center, Tehran University of Medical Science, Imam Khomeni Hospital; Tehran, Iran
² Department of Nephrology, Ziaean Hospital, Tehran, Iran

http://www.sjkdt.org/article.asp?issn=1319-2442;year=2012;volume=23;issue=5;spage=934;epage=938;aulast=Ahmadi;type=0

Abstract

Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders. Studies comparing the effects of sevelamer and nicotinic acid, both similar non-calcium and non-aluminum phosphate binders, are not available. In this study, 40 patients on HD with a serum phosphorus level of more than 6 mg/dL were enrolled. After a two week washout period without phosphate binders, the patients were randomly divided into two equal groups (n = 20) and were started on nicotinic acid or sevelamer for a period of four weeks. The dose of nicotinic acid used was 500 mg and that of sevelamer was 1600 mg daily. Blood samples were drawn for the measurement of the total calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), triglyceride (TG), total cholesterol (Chol), high-density lipoprotein (HDL), low-density lipoprotein (LDL), uric acid and parathyroid hormone (PTH). Patients receiving sevelamer showed a significant reduction in serum P level (2.2 ± 0.69 mg/dL; P <0.0001) in comparison with the nicotinic acid group (1.7 ± 1.06 mg/dL; P = 0.004). Reduction in the Ca-P product was significantly different in the two groups; in the sevelamer group, it was 21 ± 7; (P <0.0001) while in the nicotinic acid group, it was 16 ± 11 (P = 0.007). Also, patients on sevelamer showed greater reduction in the mean TG level (38.9 ± 92 mg/dL; P = 0.005). No significant changes were observed in the mean serum Ca, total Chol, HDL, LDL, ALP and iPTH levels in the two study groups. Our short-term study suggests that although nicotinic acid reduced hyperphosphatemia, sevelamer showed higher efficacy in controlling hyperphosphatemia as well as the Ca-P product.

Cefotaxime-heparin lock prophylaxis against hemodialysis catheter-related sepsis amongStaphylococcus aureus nasal carriers

Anil K Saxena¹, Bodh R Panhotra², Abdul Aziz Al-hafiz³, Dasappan S Sundaram³, Bassam Abu-Oyun³, Khalifa Al Mulhim^4
1 Nephrology Division, Al-Rahba Hospital-Johns Hopkins Medicine International, Abu Dhabi, United Arab Emirates
² Department of Microbiology, King Fahad Hospital and Tertiary Care Center, Hofuf, Al-Hassa, Eastern Province, Kingdom of Saudi Arabia
³ Nephrology Division, King Fahad Hospital and Tertiary Care Center, Hofuf, Al-Hassa, Eastern Province, Kingdom of Saudi Arabia
⁴ Department of Family Medicine, King Fahad Hospital and Tertiary Care Center, Hofuf, Al-Hassa, Eastern Province, Kingdom of Saudi Arabia

Abstract

Staphylococcus aureus nasal carriers undergoing hemodialysis (HD) through tunneled cuffed catheters (TCCs) form a high-risk group for the development of catheter-related bloodstream infections (CRBSI) and ensuing morbidity. The efficacy of antibiotic-locks on the outcomes of TCCs among S. aureus nasal carriers has not been studied earlier. Persistent nasal carriage was defined by two or more positive cultures for methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) S. aureus of five standardized nasal swabs taken from all the participants dialyzed at a large out-patient HD center affiliated to a tertiary care hospital. Of 218 participants, 82 S. aureus nasal carriers dialyzed through TCCs (n = 88) were identified through April 2005 to March 2006 and randomized to two groups. Group I comprised of 39 nasal carriers who had TCCs (n = 41) "locked" with cefotaxime/heparin while group II included 43 patients with TCCs (n = 47) filled with standard heparin. The CRBSI incidence and TCC survival at 365 days were statistically compared between the two groups. A significantly lower CRBSI incidence (1.47 vs. 3.44/1000 catheter-days, P <0.001) and higher infection-free TCC survival rates at 365 days (80.5 vs. 40.4%, P <0.0001) were observed in the cefotaxime group compared with the stan dard heparin group. However, no significant difference in MRSA-associated CRBSI incidence was observed between the two groups. Cefotaxime-heparin "locks" effectively reduced CRBSI-incidence associated with gram-positive cocci, including MSSA, among S. aureus nasal carriers. There remains a compelling requirement for antibiotic-locks effective against MRSA.